Outlook Therapeutics (OTLK)
Nasdaq Market Closed
Outlook Therapeutics, Inc. is a biopharmaceutical company focused on ophthalmology, with its lead programme centred on ONS-5010/LYTENAVA, an ophthalmic formulation of bevacizumab-gamma. The therapy is designed for retinal diseases involving abnormal blood vessel growth and leakage, particularly wet age-related macular degeneration, or wet AMD, a leading cause of vision loss in older adults.
The company’s strategy is to develop a bevacizumab product specifically formulated, manufactured, and regulated for intravitreal use in the eye. Bevacizumab has long been used in ophthalmology, but Outlook Therapeutics aims to offer an approved ophthalmic version supported by clinical and regulatory data. ONS-5010/LYTENAVA targets vascular endothelial growth factor, or VEGF, a key driver of wet AMD, placing it within the anti-VEGF class that is central to modern retinal care.
Outlook Therapeutics has received marketing authorisation for LYTENAVA for the treatment of wet AMD in the European Union and the United Kingdom. Its broader development and commercial plans focus on advancing the product through regulatory pathways and positioning it within a market served by established injectable retinal therapies. The company’s clinical work includes studies under the NORSE programme, designed to evaluate safety and efficacy in ophthalmic indications.
For investors, OTLK is a specialised biotechnology stock whose outlook is closely linked to regulatory milestones, clinical results, manufacturing readiness, reimbursement, and commercial adoption by retina specialists. The company stands out for concentrating on a defined product opportunity in anti-VEGF eye care rather than maintaining a broad drug-development pipeline.
Last updated
- Market Cap
- 120.36M
- P/E
- —
- P/FCF
- —
- P/S
- 283.24
- Enterprise Value
- 139.58M
- Sector
- Health Care
- Industry
- Biological Products, Except Diagnostic Substances
- Address
- 111 S. WOOD AVENUE, ISELIN, NJ, 08830
Outlook Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Innovations in Imaging, such as AI-Enhanced Retinal & Fundus Camera Systems are Booming Along with Revenue Opportunities
Outlook Therapeutics® to Present at the Virtual Investor Pitch Conference
Outlook Therapeutics® Receives European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD
Outlook Therapeutics® Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMD
Outlook Therapeutics® to Report Financial Results for Second Quarter Fiscal Year 2024 on May 16, 2024 and Host Inaugural Quarterly Conference Call and Webcast
Outlook Therapeutics® to Present at the Retina World Congress 2024
Outlook Therapeutics® Announces Closing of Private Placement of $5.0 Million
Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD
All You Need to Know About Oncobiologics (OTLK) Rating Upgrade to Buy
Outlook Therapeutics® Announces Closing of Private Placement of up to $159 Million
Outlook Therapeutics® Announces Effective Date for 1-for-20 Reverse Stock Split
Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2024 and Provides Corporate Update
Outlook Therapeutics® Doses First Subject in NORSE EIGHT
Outlook (OTLK) Surges 31% on Regulatory Update for AMD Study
Outlook Therapeutics® Reports Financial Results for Fiscal Year 2023 and Reiterates ONS-5010 Clinical and Regulatory Path Forward in the U.S. and EU
Outlook Therapeutics® Submits Special Protocol Assessment (SPA) to FDA for Non-Inferiority Study of ONS-5010
Outlook Therapeutics® Announces Strategic Organizational Realignment
Best Penny Stocks To Buy Today? 3 To Watch This Week
Outlook Therapeutics® Announces Receipt of Type A Meeting Minutes and Reiterates Regulatory Path Forward for ONS-5010
- Market Cap
Market cap is the total value of a company's shares, calculated by multiplying the stock price by the number of shares outstanding.
- 120.36M
- Enterprise Value
Enterprise value is the total value of a company, including its market cap, debt, and cash.
- 139.58M
- P/E
P/E ratio compares a company's share price to its earnings per share.
- —
- P/B
P/B ratio compares a company's share price to its book value per share.
- -4.15
- P/S
P/S ratio compares a company's share price to its revenue per share.
- 283.24
- EV / EBITDA
EV/EBITDA measures a company's value compared to its earnings before interest, taxes, depreciation, and amortization.
- -3.24
- EV / Sales
EV/Sales measures a company's value compared to its total revenue.
- 328.47
- EPS
- -0.32
- Dividend Yield
Dividend yield shows how much a company pays in dividends each year compared to its share price.
- 0%
- P/FCF
Price-to-free-cash-flow ratio compares a company's share price to the cash it generates after expenses and investments.
- —
- P/CF
P/CF ratio compares a company's share price to the cash flow it generates from its operations.
- —
- Free Cash Flow
Free cash flow is the cash a company has left after covering operating costs and capital expenses.
- —
- ROE
ROE measures how effectively a company uses shareholders' equity to generate profit.
- 164.39%
- ROA
ROA measures how effectively a company uses its assets to generate profit.
- -217.72%
- Debt / Equity
Debt-to-equity ratio compares a company's total debt to its shareholders' equity.
- -0.93
- Current Ratio
Current ratio measures a company's ability to pay short-term debts using its short-term assets.
- 0.54
- Quick Ratio
Quick ratio measures a company's ability to pay short-term debts using cash and other easily available assets.
- 0.45
- Cash
Cash ratio measures a company's ability to cover short-term debts using only cash and cash equivalents.
- 0.2
- Avg Volume
Average volume shows the average number of shares traded over the last 30 trading days, helping indicate liquidity.
- 25.53M
- Fundamentals Snapshot Price
Fundamentals snapshot price is the stock price used when calculating the company's financial ratios and metrics.
- 0.81
Income Statement
| Line Item | 2026 Q2 | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 |
|---|---|---|---|---|---|
| Revenue | 127.44K | -1.21M | — | 1.51M | — |
| Gross profit | -21.89K | -1.24M | — | 1.07M | — |
| Operating income | -14.03M | -13.48M | — | -15.75M | -12.39M |
| EBITDA | -14M | -13.45M | 29.74K | -15.72M | -12.36M |
| Net income | -4.45M | -23.06M | — | -20.15M | -46.36M |
| Basic EPS | -0.05 | -0.38 | — | -0.55 | -1.5 |
| Diluted EPS | -0.05 | -0.38 | — | -0.55 | -1.5 |
Balance Sheet
| Line Item | 2026 Q2 | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 |
|---|---|---|---|---|---|
| Total assets | 21.89M | 18.24M | 18.58M | 22.39M | 19.08M |
| Total liabilities | 50.89M | 56.79M | 50.77M | 59.58M | 51.54M |
| Total equity | -28.99M | -38.55M | -32.19M | -37.19M | -32.46M |
| Cash & equivalents | 7.75M | 8.68M | 8.08M | 8.9M | 7.56M |
| Current assets | 20.9M | 17.17M | 17.39M | 21.1M | 17.81M |
| Current liabilities | 38.88M | 49.06M | 45.81M | 31.49M | 24.82M |
Cash Flow
| Line Item | 2026 Q2 | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 |
|---|---|---|---|---|---|
| Operating cash flow | -7.83M | -14.94M | -12.38M | -11.9M | -16.58M |
| Investing cash flow | — | — | — | — | — |
| Financing cash flow | 6.9M | 15.53M | 11.56M | 13.25M | 18.44M |
| Change in cash | -929.2K | 594.34K | -817.73K | 1.34M | 1.85M |
| Kind | Filing | Date | Link |
|---|---|---|---|
| edgar index | 4 — Outlook Therapeutics, Inc. | View Filing | |
| edgar index | SCHEDULE 13D/A — Outlook Therapeutics, Inc. | View Filing | |
| edgar index | 8-K — Outlook Therapeutics, Inc. | View Filing | |
| edgar index | DEF 14A — Outlook Therapeutics, Inc. | View Filing | |
| edgar index | DEFA14A — Outlook Therapeutics, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 424B5 — Outlook Therapeutics, Inc. | View Filing | |
| edgar index | 8-K — Outlook Therapeutics, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — Outlook Therapeutics, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| form 4 | Form 4 — Sukhtian Ghiath M. | View Filing | |
| form 4 | Form 4 — GMS Ventures & Investments | View Filing | |
| form 4 | Form 4 — GMS Ventures & Investments | View Filing | |
| form 4 | Form 4 — GMS Ventures & Investments | View Filing | |
| form 4 | Form 4 — Sukhtian Ghiath M. | View Filing | |
| form 4 | Form 4 — Sukhtian Ghiath M. | View Filing | |
| form 4 | Form 4 — GMS Ventures & Investments | View Filing | |
| form 4 | Form 4 — Sukhtian Ghiath M. | View Filing | |
| form 4 | Form 4 — Sukhtian Ghiath M. | View Filing | |
| form 4 | Form 4 — GMS Ventures & Investments | View Filing | |
| form 4 | Form 4 — Sukhtian Ghiath M. | View Filing | |
| form 4 | Form 4 — Sukhtian Ghiath M. | View Filing | |
| form 4 | Form 4 — GMS Ventures & Investments | View Filing | |
| form 4 | Form 4 — GMS Ventures & Investments | View Filing | |
| edgar index | 4 — Outlook Therapeutics, Inc. | View Filing | |
| edgar index | 4 — Outlook Therapeutics, Inc. | View Filing | |
| edgar index | 4 — Outlook Therapeutics, Inc. | View Filing | |
| edgar index | 4 — Outlook Therapeutics, Inc. | View Filing | |
| form 4 | Form 4 — Sukhtian Faisal Ghiath | View Filing | |
| edgar index | 8-K — Outlook Therapeutics, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| form 4 | Form 4 — HILZINGER KURT J | View Filing | |
| form 4 | Form 4 — THURMAN RANDY H | View Filing | |
| form 4 | Form 4 — Haddadin Yezan Munther | View Filing | |
| edgar index | PRE 14A — Outlook Therapeutics, Inc. | View Filing | |
| edgar index | 8-K — Outlook Therapeutics, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 10-Q — Outlook Therapeutics, Inc. | View Filing | |
| edgar index | 8-K — Outlook Therapeutics, Inc. | View Filing | |
| edgar index | 424B5 — Outlook Therapeutics, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | D — Outlook Therapeutics, Inc. | View Filing | |
| edgar index | SCHEDULE 13G — Outlook Therapeutics, Inc. | View Filing | |
| edgar index | 424B5 — Outlook Therapeutics, Inc. | View Filing | |
| edgar index | 8-K — Outlook Therapeutics, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — Outlook Therapeutics, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — Outlook Therapeutics, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 424B5 — Outlook Therapeutics, Inc. | View Filing | |
| edgar index | 8-K — Outlook Therapeutics, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 424B5 — Outlook Therapeutics, Inc. | View Filing | |
| edgar index | 8-K — Outlook Therapeutics, Inc. | View Filing | |
| edgar index | 8-K — Outlook Therapeutics, Inc. | View Filing | |
| edgar index | 8-K — Outlook Therapeutics, Inc. | View Filing | |
| edgar index | 8-K — Outlook Therapeutics, Inc. | View Filing | |
| edgar index | 8-K — Outlook Therapeutics, Inc. | View Filing | |
| edgar index | 8-K — Outlook Therapeutics, Inc. | View Filing | |
| edgar index | 10-Q — Outlook Therapeutics, Inc. | View Filing | |
| edgar index | 8-K — Outlook Therapeutics, Inc. | View Filing | |
| edgar index | SCHEDULE 13G/A — Outlook Therapeutics, Inc. | View Filing | |
| edgar index | DEF 14A — Outlook Therapeutics, Inc. | View Filing | |
| edgar index | DEFA14A — Outlook Therapeutics, Inc. | View Filing | |
| edgar index | ARS — Outlook Therapeutics, Inc. | View Filing | |
| edgar index | 8-K — Outlook Therapeutics, Inc. | View Filing | |
| edgar index | 8-K — Outlook Therapeutics, Inc. | View Filing | |
| edgar index | 10-K — Outlook Therapeutics, Inc. | View Filing | |
| ten k section | 10-K — business | View Filing | |
| ten k section | 10-K — risk_factors | View Filing | |
| edgar index | 8-K — Outlook Therapeutics, Inc. | View Filing | |
| edgar index | 8-K — Outlook Therapeutics, Inc. | View Filing | |
| edgar index | SCHEDULE 13G/A — Outlook Therapeutics, Inc. | View Filing |